SCHEMBL6086196

SCHEMBL6086196

N=C(c1cc2cccc(N3CCCCC3)c2o1)N(O)c1cccc(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ2 O43526 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.40
HPGD P15428 3/20 0.40
GAA P10253 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CSF1R P07333 1/20 0.37
KDM4E B2RXH2 3/20 0.36
NPSR1 Q6W5P4 3/20 0.36
NPC1 O15118 3/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPT P10636 3/20 0.36
ATM Q13315 2/20 0.36
TP53 P04637 1/20 0.36
HTT P42858 1/20 0.36
SLC9A1 P19634 2/20 0.35
RAB9A P51151 3/20 0.34
PKM P14618 1/20 0.34
MAOB P27338 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7593048 0.80 KCNQ2 (0.38) KCNQ2SMN1; SMN2HPGDGAAMEN1
SCHEMBL7586241 0.79 HTR3E (0.40) MEN1KMT2ANPC1ALDH1A1MAPT
SCHEMBL7585802 0.76 LMNA (0.51) SMN1; SMN2HPGDMEN1KMT2AKDM4E
SCHEMBL7582051 0.74 GPR35 (0.41) SMN1; SMN2HPGDMEN1KMT2AKDM4E
SCHEMBL5866940 0.73 KCNQ2 (0.46) KCNQ2SMN1; SMN2HPGDGAAMEN1
SCHEMBL5866939 0.73 KCNQ2 (0.46) KCNQ2SMN1; SMN2HPGDGAAMEN1
SCHEMBL6086523 0.73 HTR3E (0.42) SMN1; SMN2KMT2AKDM4ENPC1ALDH1A1
SCHEMBL6777820 0.72 KEAP1 (0.40) SMN1; SMN2HPGDMEN1KMT2AKDM4E
SCHEMBL5866943 0.71 KCNQ2 (0.43) KCNQ2SMN1; SMN2HPGDGAAMEN1
SCHEMBL5867030 0.71 KDM4E (0.48) KCNQ2SMN1; SMN2HPGDGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7148259-B1 Antibacterial agents AMGEN INC. (US) 2006-12-12 US disclosed
US-20040235911-A1 hydroxyamidines; antibiotic resistance TULARIK INC. 2004-11-25 US disclosed
EP-1246795-A2 ANTIBACTERIAL AGENTS Tularik Inc. (US) 2002-10-09 EP disclosed
WO-2001051456-A2 ANTIBACTERIAL AGENTS TULARIK INC. (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235911-A1 hydroxyamidines; antibiotic resistance HNMT, HDHD5, ABCC1 KCNQ2 4019/4885SMN1; SMN2 2862/4885HPGD 958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.